HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform

This article was originally published in The Tan Sheet

Executive Summary

Generic drug user fees should be considered only in the context of changes to Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA at a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.

You may also be interested in...



PDUFA meeting

FDA to hear stakeholder testimony Dec. 7 in Bethesda, Md., on what aspects of user fee program should be retained or changed and whether program should allow use of user fee funding to monitor post-approval drug safety. Agency also seeks input on how it can ensure PDUFA goals are met in wake of continued funding shortfalls and whether there should be flexibility in setting user fees to cover increased program costs. PDUFA legislative authority sunsets in September 2002; FDA held a similar public meeting last year (1"The Tan Sheet" Sept. 25, 2000, p. 8)...

NAPM/GPhA Merger Likely Ends Generic User Fees Push In 107th

The merger agreement between the National Association of Pharmaceutical Manufacturers and the Generic Pharmaceutical Association likely means generic drug user fees will not be a focal point of the PDUFA reauthorization process.

GPIA/NPA Merger Seeks Unified Generic Industry Voice, Without NAPM

The Generic Pharmaceutical Industry Association and the National Pharmaceutical Alliance hope that by merging they will move closer to establishing a unified voice for the generic industry on the eve of legislative debates over user fees and Waxman/Hatch reform.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel